Core Laboratories Inc.
CLB
$11.86
$0.252.15%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 129.24M | 134.40M | 130.58M | 129.64M | 128.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 129.24M | 134.40M | 130.58M | 129.64M | 128.21M |
| Cost of Revenue | 106.20M | 106.81M | 102.93M | 104.59M | 101.52M |
| Gross Profit | 23.04M | 27.59M | 27.65M | 25.05M | 26.69M |
| SG&A Expenses | 8.79M | 8.33M | 9.97M | 11.50M | 8.29M |
| Depreciation & Amortization | 3.66M | 3.68M | 3.77M | 3.84M | 3.87M |
| Other Operating Expenses | -221.00K | -1.01M | -887.00K | -203.00K | -371.00K |
| Total Operating Expenses | 118.44M | 117.80M | 115.79M | 119.73M | 113.31M |
| Operating Income | 10.80M | 16.60M | 14.79M | 9.91M | 14.90M |
| Income Before Tax | 11.55M | 16.70M | 12.80M | 5.15M | 10.96M |
| Income Tax Expenses | 4.08M | 4.69M | 3.61M | 1.66M | 8.53M |
| Earnings from Continuing Operations | 7.47M | 12.00M | 9.19M | 3.49M | 2.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -66.00K | -259.00K | -158.00K | -270.00K | -235.00K |
| Net Income | 7.40M | 11.75M | 9.03M | 3.22M | 2.20M |
| EBIT | 10.80M | 16.60M | 14.79M | 9.91M | 14.90M |
| EBITDA | 14.47M | 20.27M | 18.56M | 13.75M | 18.77M |
| EPS Basic | 0.16 | 0.25 | 0.19 | 0.07 | 0.05 |
| Normalized Basic EPS | 0.10 | 0.18 | 0.15 | 0.08 | 0.14 |
| EPS Diluted | 0.16 | 0.25 | 0.19 | 0.07 | 0.04 |
| Normalized Diluted EPS | 0.10 | 0.18 | 0.14 | 0.08 | 0.14 |
| Average Basic Shares Outstanding | 47.77M | 46.92M | 46.91M | 46.86M | 47.56M |
| Average Diluted Shares Outstanding | 47.77M | 47.82M | 47.74M | 47.70M | 47.56M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 6.34% | 3.99% | 5.20% | 14.53% | 21.24% |